Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track StatusCARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (
NASDAQBDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). The news follows Biodexa reporting positive 12-month data from a phase 2 clinical trial in July 2024, as previously covered by Benzinga.
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the ClinicCARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (
NASDAQBDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer.
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (
NASDAQBDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BDRX.
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (
NASDAQBDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain CancerIn a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month DataCARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (
NASDAQBDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making good progress with eRapa™, its drug to treat Familial Adenomatous Polyposis (FAP).
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal CancerCARDIFF, UK / ACCESSWIRE / June 3, 2024 / Biodexa Pharmaceuticals (
NASDAQBDRX) just announced promising phase 2 results for its newly in-licensed drug eRapa for treating familial adenomatous polyposis (FAP), a mainly genetic disease of the lower GI tract for which there is currently no remedy except surgical removal of the colon and/or rectum.
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate TolimidoneOrally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of EquityBiodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Exercise of Pre-Funded Warrants and Issue of Equity Total Voting Rights
